Search
Retifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigationalRetifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed … [L45603,L45613] The use of retifanlimab in combination with other oncology drugs for the treatment of metastatic gastroesophageal adenocarcinoma has also been evaluated.[A258383,A258388]
Categories: Programmed Death Receptor-1 Blocking AntibodyHepatocyte nuclear factor 4-gamma
go.drugbank.com/bio_entities/BE0003179TargetHumansTranscription factor. Has a lower transcription activation potential than HNF4-alpha
Synonyms: Nuclear receptor subfamily 2 group A member 2Guanidine
go.drugbank.com/drugs/DB00536ApprovedIt is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. … (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.
Reversin 121
go.drugbank.com/drugs/DB14072ExperimentalReversin 121 is a hydrophobic peptide chemosensitizer that can reverse P-glycoprotein-mediated multidrug resistance.
Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen
go.drugbank.com/drugs/DB16902ApprovedUpon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16903ApprovedWithdrawnUpon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16910ApprovedUpon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16914ApprovedWithdrawnUpon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Delaware/55/2019 CVR-45 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16915ApprovedWithdrawnUpon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen